January 6, 2015 Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker June 1, 2015 Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarke
In Recognition of 10th Anniversary, Raymond Woosley and Janet Woodcock Address CPAD Consortium’s 2018 Annual Meeting and Regulatory Science Workshop At its 10th Annual Meeting and Regulatory Science Workshop, November 13, 2018, in Bethesda, MD, C-Path’s Critical Path for Alzhe
C-Path Cosponsors Workshop on Combination Drug Development for Alzheimer’s Disease Combination therapy development has been successful in other life-threatening diseases in part because collaborative approaches we
“Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK”
Collaboration is Making LIFE Better: Critical Path Institute Celebrates Key Milestones AZ Bionindustry Association
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administratio
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)
eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Administering Complex Cognitive Tests Remotely in The Cognitively-Impair